Hinge Health (HNGE) Rises +9% Over the Past 30 Days on Growth Momentum
Key Takeaways
- HNGE shares have climbed roughly 9% over the trailing 30 days, holding near 52-week highs after a powerful 2026 run.
- Second-quarter 2026 revenue rose 53% year over year to $213 million, while operating margin expanded to 29% from 19%.
- The company signed a definitive agreement to acquire Cylinder Health for $105 million in cash, adding gastrointestinal care to its platform.
- Full-year 2026 revenue guidance was raised to $856 million–$860 million, with non-GAAP operating income guided to $236 million–$244 million.
- Analyst sentiment has turned constructive, with several firms issuing Buy ratings and raising price targets.
Where HNGE Stands in the Market Right Now
Hinge Health shares recently traded near $97.95, within striking distance of their 52-week highs and up roughly 9% over the prior 30 days. That short-term move extends a substantially larger year-to-date advance, reflecting strong demand for the stock after a record quarterly report and an upward revision to full-year guidance. The stock's elevated price-to-earnings multiple—in the range of roughly 70 times—signals that investors are pricing in continued rapid growth and margin expansion rather than current profitability alone. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Hinge Health’s (HNGE) Business and Competitive Position
Hinge Health is a digital healthcare company focused on musculoskeletal (MSK) health, covering the spectrum from acute injury and chronic pain to post-surgical rehabilitation. Its core platform, built around AI-powered motion-tracking technology and the Enso wearable for non-addictive pain relief, pairs software with a care team of licensed physical therapists, physicians, and health coaches. Founded in 2014 and headquartered in San Francisco, the company serves employers and health plans and has expanded into adjacent care categories, including migraine and gastrointestinal health. Its strategy centers on automating care delivery to improve member outcomes while lowering costs for clients, positioning Hinge Health as one of the most prominent names in virtual-first MSK care.
Key Drivers Behind Recent HNGE Momentum
The most significant recent catalyst was Hinge Health's second-quarter 2026 report, which showed revenue of $213 million—up 53% year over year and above the company's prior guidance range. Operating income more than doubled to $62 million, gross margin reached 87%, and free cash flow climbed to $100 million from $33 million a year earlier. Last-twelve-month calculated billings rose 52% to $862 million, a leading indicator management highlights for future revenue growth. From what I see, these results underscore the durability of the company’s growth trajectory.
Alongside the results, Hinge Health raised its 2026 outlook, citing durable improvements in member engagement, or "yield." The company now expects full-year revenue of $856 million to $860 million and non-GAAP operating income of $236 million to $244 million. Management also announced a $300 million share-repurchase authorization after repurchasing roughly 480,000 shares for $26 million during the quarter.
The company's expansion strategy has drawn particular attention. Hinge Health signed a definitive agreement to acquire Cylinder Health, a virtual-first gastrointestinal care provider with nearly 100 clients covering about 2 million lives, for $105 million in cash. The deal is expected to contribute roughly $7 million to $8 million of revenue in 2026, with broader scaling anticipated in 2027 and beyond. Separately, the company's newer Migraine Care Program has enrolled more than 450 clients covering over 5 million lives. Analyst activity has reflected this momentum, with Bank of America initiating coverage with a Buy rating and a $110 target, while Stifel and Needham raised their price targets to $115.
2026 Outlook and Areas Investors Should Monitor
Looking ahead, investors will likely focus on the third-quarter 2026 report, where management has guided to revenue of $223 million to $225 million—roughly 45% growth at the midpoint. Sustained yield improvements, growth in eligible lives, and average selling price per member remain the key drivers of the company's billings trajectory. I’m watching this closely as execution on these fronts will determine whether the current valuation holds.
The Cylinder Health integration is another area to monitor, with completion targeted by summer 2027 and a broader gastrointestinal rollout planned for 2027. Because the business is expected to operate at a loss initially, execution on integration and its path toward Hinge Health's profitability profile will be closely watched. Broader themes—including employer and health-plan budget cycles, competition in virtual care, and healthcare spending conditions—also matter for the company's land-and-expand model. At current valuation levels, continued delivery on growth and margin targets will be central to how the market assesses the stock's premium.
Exploring Tickeron’s Trending AI Robots
In my analysis of names like HNGE, I often turn to Tickeron’s Trending AI Robots page for an additional perspective. It surfaces a selection of high-performing AI-driven trading bots that cover various strategies and timeframes, helping me evaluate momentum signals alongside traditional research. This resource has become a useful part of my routine when assessing growth stocks in the healthcare space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for HNGE turns positive, indicating new upward trend
HNGE saw its Momentum Indicator move above the 0 level on September 29, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator turned positive. In 22 of the 24 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for HNGE just turned positive on October 01, 2026. Looking at past instances where HNGE's MACD turned positive, the stock continued to rise in 8 of 10 cases over the following month. The odds of a continued upward trend are 80%.
Following a +6.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where HNGE advanced for three days, in 76 of 90 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 52 of 61 cases where HNGE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HNGE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
HNGE broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 25 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. HNGE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: HNGE's P/B Ratio (21.645) is slightly higher than the industry average of (7.432). HNGE has a moderately low P/E Ratio (11.247) as compared to the industry average of (46.656). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (10.504) is also within normal values, averaging (6.065).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HNGE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement